Genetic resistance to purine nucleoside phosphorylase inhibition in plasmodium falciparum

Rodrigo G. Ducati, Hilda A. Namanja-Magliano, Rajesh K. Harijan, J. Eduardo Fajardo, Andras Fiser, Johanna P. Daily, Vern L. Schramm

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Plasmodium falciparum causes the most lethal form of human malaria and is a global health concern. The parasite responds to antimalarial therapies by developing drug resistance. The continuous development of new antimalarials with novel mechanisms of action is a priority for drug combination therapies. The use of transition-state analog inhibitors to block essential steps in purine salvage has been proposed as a new antimalarial approach. Mutations that reduce transition-state analog binding are also expected to reduce the essential catalytic function of the target. We have previously reported that inhibition of host and P. falciparum purine nucleoside phosphorylase (PfPNP) by DADMe-Immucillin-G (DADMe-ImmG) causes purine starvation and parasite death in vitro and in primate infection models. P. falciparum cultured under incremental DADMe-ImmG drug pressure initially exhibited increased PfPNP gene copy number and protein expression. At increased drug pressure, additional PfPNP gene copies appeared with point mutations at catalytic site residues involved in drug binding. Mutant PfPNPs from resistant clones demonstrated reduced affinity for DADMe-ImmG, but also reduced catalytic efficiency. The catalytic defects were partially overcome by gene amplification in the region expressing PfPNP. Crystal structures of native and mutated PfPNPs demonstrate altered catalytic site contacts to DADMe-ImmG. Both point mutations and gene amplification are required to overcome purine starvation induced by DADMe-ImmG. Resistance developed slowly, over 136 generations (2136 clonal selection). Transition-state analog inhibitors against PfPNP are slow to induce resistance and May have promise in malaria therapy.

Original languageEnglish (US)
Pages (from-to)2114-2119
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume115
Issue number9
DOIs
StatePublished - Feb 27 2018

Fingerprint

Purine-Nucleoside Phosphorylase
Plasmodium falciparum
Antimalarials
Gene Amplification
Starvation
Point Mutation
Malaria
Catalytic Domain
Parasites
Pharmaceutical Preparations
Pressure
Gene Dosage
Combination Drug Therapy
Drug Resistance
Primates
Clone Cells
4'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)immucillin G
Mutation
Therapeutics
Infection

Keywords

  • Drug resistance
  • Gene amplification
  • Gene mutation
  • Genetic resistance mechanisms
  • Malaria

ASJC Scopus subject areas

  • General

Cite this

Genetic resistance to purine nucleoside phosphorylase inhibition in plasmodium falciparum. / Ducati, Rodrigo G.; Namanja-Magliano, Hilda A.; Harijan, Rajesh K.; Eduardo Fajardo, J.; Fiser, Andras; Daily, Johanna P.; Schramm, Vern L.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 115, No. 9, 27.02.2018, p. 2114-2119.

Research output: Contribution to journalArticle

@article{b5af59b234184316a1fb7e51f87f4a9b,
title = "Genetic resistance to purine nucleoside phosphorylase inhibition in plasmodium falciparum",
abstract = "Plasmodium falciparum causes the most lethal form of human malaria and is a global health concern. The parasite responds to antimalarial therapies by developing drug resistance. The continuous development of new antimalarials with novel mechanisms of action is a priority for drug combination therapies. The use of transition-state analog inhibitors to block essential steps in purine salvage has been proposed as a new antimalarial approach. Mutations that reduce transition-state analog binding are also expected to reduce the essential catalytic function of the target. We have previously reported that inhibition of host and P. falciparum purine nucleoside phosphorylase (PfPNP) by DADMe-Immucillin-G (DADMe-ImmG) causes purine starvation and parasite death in vitro and in primate infection models. P. falciparum cultured under incremental DADMe-ImmG drug pressure initially exhibited increased PfPNP gene copy number and protein expression. At increased drug pressure, additional PfPNP gene copies appeared with point mutations at catalytic site residues involved in drug binding. Mutant PfPNPs from resistant clones demonstrated reduced affinity for DADMe-ImmG, but also reduced catalytic efficiency. The catalytic defects were partially overcome by gene amplification in the region expressing PfPNP. Crystal structures of native and mutated PfPNPs demonstrate altered catalytic site contacts to DADMe-ImmG. Both point mutations and gene amplification are required to overcome purine starvation induced by DADMe-ImmG. Resistance developed slowly, over 136 generations (2136 clonal selection). Transition-state analog inhibitors against PfPNP are slow to induce resistance and May have promise in malaria therapy.",
keywords = "Drug resistance, Gene amplification, Gene mutation, Genetic resistance mechanisms, Malaria",
author = "Ducati, {Rodrigo G.} and Namanja-Magliano, {Hilda A.} and Harijan, {Rajesh K.} and {Eduardo Fajardo}, J. and Andras Fiser and Daily, {Johanna P.} and Schramm, {Vern L.}",
year = "2018",
month = "2",
day = "27",
doi = "10.1073/pnas.1525670115",
language = "English (US)",
volume = "115",
pages = "2114--2119",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "9",

}

TY - JOUR

T1 - Genetic resistance to purine nucleoside phosphorylase inhibition in plasmodium falciparum

AU - Ducati, Rodrigo G.

AU - Namanja-Magliano, Hilda A.

AU - Harijan, Rajesh K.

AU - Eduardo Fajardo, J.

AU - Fiser, Andras

AU - Daily, Johanna P.

AU - Schramm, Vern L.

PY - 2018/2/27

Y1 - 2018/2/27

N2 - Plasmodium falciparum causes the most lethal form of human malaria and is a global health concern. The parasite responds to antimalarial therapies by developing drug resistance. The continuous development of new antimalarials with novel mechanisms of action is a priority for drug combination therapies. The use of transition-state analog inhibitors to block essential steps in purine salvage has been proposed as a new antimalarial approach. Mutations that reduce transition-state analog binding are also expected to reduce the essential catalytic function of the target. We have previously reported that inhibition of host and P. falciparum purine nucleoside phosphorylase (PfPNP) by DADMe-Immucillin-G (DADMe-ImmG) causes purine starvation and parasite death in vitro and in primate infection models. P. falciparum cultured under incremental DADMe-ImmG drug pressure initially exhibited increased PfPNP gene copy number and protein expression. At increased drug pressure, additional PfPNP gene copies appeared with point mutations at catalytic site residues involved in drug binding. Mutant PfPNPs from resistant clones demonstrated reduced affinity for DADMe-ImmG, but also reduced catalytic efficiency. The catalytic defects were partially overcome by gene amplification in the region expressing PfPNP. Crystal structures of native and mutated PfPNPs demonstrate altered catalytic site contacts to DADMe-ImmG. Both point mutations and gene amplification are required to overcome purine starvation induced by DADMe-ImmG. Resistance developed slowly, over 136 generations (2136 clonal selection). Transition-state analog inhibitors against PfPNP are slow to induce resistance and May have promise in malaria therapy.

AB - Plasmodium falciparum causes the most lethal form of human malaria and is a global health concern. The parasite responds to antimalarial therapies by developing drug resistance. The continuous development of new antimalarials with novel mechanisms of action is a priority for drug combination therapies. The use of transition-state analog inhibitors to block essential steps in purine salvage has been proposed as a new antimalarial approach. Mutations that reduce transition-state analog binding are also expected to reduce the essential catalytic function of the target. We have previously reported that inhibition of host and P. falciparum purine nucleoside phosphorylase (PfPNP) by DADMe-Immucillin-G (DADMe-ImmG) causes purine starvation and parasite death in vitro and in primate infection models. P. falciparum cultured under incremental DADMe-ImmG drug pressure initially exhibited increased PfPNP gene copy number and protein expression. At increased drug pressure, additional PfPNP gene copies appeared with point mutations at catalytic site residues involved in drug binding. Mutant PfPNPs from resistant clones demonstrated reduced affinity for DADMe-ImmG, but also reduced catalytic efficiency. The catalytic defects were partially overcome by gene amplification in the region expressing PfPNP. Crystal structures of native and mutated PfPNPs demonstrate altered catalytic site contacts to DADMe-ImmG. Both point mutations and gene amplification are required to overcome purine starvation induced by DADMe-ImmG. Resistance developed slowly, over 136 generations (2136 clonal selection). Transition-state analog inhibitors against PfPNP are slow to induce resistance and May have promise in malaria therapy.

KW - Drug resistance

KW - Gene amplification

KW - Gene mutation

KW - Genetic resistance mechanisms

KW - Malaria

UR - http://www.scopus.com/inward/record.url?scp=85042689190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042689190&partnerID=8YFLogxK

U2 - 10.1073/pnas.1525670115

DO - 10.1073/pnas.1525670115

M3 - Article

C2 - 29440412

AN - SCOPUS:85042689190

VL - 115

SP - 2114

EP - 2119

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 9

ER -